veracyte inc - VCYT
VCYT
Close Chg Chg %
42.92 -0.15 -0.35%
Pre-Market
42.77
-0.15 (0.35%)
Volume: 260.60K
Last Updated:
Dec 24, 2025, 1:00 PM EDT
Company Overview: veracyte inc - VCYT
VCYT Key Data
| Open $42.62 | Day Range 42.11 - 43.00 |
| 52 Week Range 22.61 - 50.71 | Market Cap $3.39B |
| Shares Outstanding 79.05M | Public Float 77.34M |
| Beta 1.83 | Rev. Per Employee N/A |
| P/E Ratio 113.48 | EPS $0.39 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 859.46K |
VCYT Performance
| 1 Week | -0.35% | ||
| 1 Month | -9.65% | ||
| 3 Months | 27.90% | ||
| 1 Year | 6.61% | ||
| 5 Years | -23.35% |
VCYT Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
13
Full Ratings ➔
About veracyte inc - VCYT
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
VCYT At a Glance
Veracyte, Inc.
6000 Shoreline Court
South San Francisco, California 94080
| Phone | 1-650-243-6300 | Revenue | 445.76M | |
| Industry | Medical Specialties | Net Income | 24.14M | |
| Sector | Health Technology | 2024 Sales Growth | 23.463% | |
| Fiscal Year-end | 12 / 2025 | Employees | 824 | |
| View SEC Filings |
VCYT Valuation
| P/E Current | 113.484 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 128.238 |
| Price to Sales Ratio | 6.944 |
| Price to Book Ratio | 2.619 |
| Price to Cash Flow Ratio | 41.22 |
| Enterprise Value to EBITDA | 50.405 |
| Enterprise Value to Sales | 6.408 |
| Total Debt to Enterprise Value | 0.018 |
VCYT Efficiency
| Revenue/Employee | 540,975.728 |
| Income Per Employee | 29,293.689 |
| Receivables Turnover | 8.771 |
| Total Asset Turnover | 0.361 |
VCYT Liquidity
| Current Ratio | 4.734 |
| Quick Ratio | 4.458 |
| Cash Ratio | 3.681 |
VCYT Profitability
| Gross Margin | 64.955 |
| Operating Margin | 7.451 |
| Pretax Margin | 5.775 |
| Net Margin | 5.415 |
| Return on Assets | 1.953 |
| Return on Equity | 2.175 |
| Return on Total Capital | 1.968 |
| Return on Invested Capital | 2.126 |
VCYT Capital Structure
| Total Debt to Total Equity | 4.314 |
| Total Debt to Total Capital | 4.136 |
| Total Debt to Total Assets | 3.803 |
| Long-Term Debt to Equity | 3.677 |
| Long-Term Debt to Total Capital | 3.525 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Veracyte Inc - VCYT
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 219.51M | 296.54M | 361.05M | 445.76M | |
Sales Growth
| +86.85% | +35.09% | +21.76% | +23.46% | |
Cost of Goods Sold (COGS) incl D&A
| 92.54M | 125.70M | 137.90M | 156.22M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 21.23M | 29.25M | 27.19M | 23.46M | |
Depreciation
| 5.24M | 7.89M | 6.62M | 8.61M | |
Amortization of Intangibles
| 15.98M | 21.35M | 20.57M | 14.85M | |
COGS Growth
| +95.91% | +35.83% | +9.70% | +13.28% | |
Gross Income
| 126.97M | 170.83M | 223.15M | 289.55M | |
Gross Income Growth
| +80.75% | +34.54% | +30.63% | +29.75% | |
Gross Profit Margin
| +57.84% | +57.61% | +61.81% | +64.95% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 185.96M | 208.44M | 235.22M | 256.33M | |
Research & Development
| 29.53M | 40.08M | 56.37M | 68.02M | |
Other SG&A
| 156.43M | 168.36M | 178.85M | 188.31M | |
SGA Growth
| +82.24% | +12.09% | +12.85% | +8.98% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 22.91M | 3.47M | 73.73M | 17.07M | |
EBIT after Unusual Expense
| (81.90M) | (41.08M) | (85.80M) | 16.14M | |
Non Operating Income/Expense
| 495.00K | 4.85M | 9.20M | 9.60M | |
Non-Operating Interest Income
| 135.00K | 1.97M | 7.34M | 11.15M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 241.00K | 198.00K | 15.00K | 2.00K | |
Interest Expense Growth
| +5.24% | -17.84% | -92.42% | -86.67% | |
Gross Interest Expense
| 241.00K | 198.00K | 15.00K | 2.00K | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (81.65M) | (36.43M) | (76.61M) | 25.74M | |
Pretax Income Growth
| -133.89% | +55.39% | -110.32% | +133.60% | |
Pretax Margin
| -37.20% | -12.28% | -21.22% | +5.78% | |
Income Tax
| (6.09M) | 133.00K | (2.21M) | 1.61M | |
Income Tax - Current - Domestic
| 63.00K | 426.00K | 1.52M | 1.81M | |
Income Tax - Current - Foreign
| 54.00K | 134.00K | 193.00K | 22.00K | |
Income Tax - Deferred - Domestic
| (4.03M) | 118.00K | (90.00K) | (230.00K) | |
Income Tax - Deferred - Foreign
| - | (2.17M) | (545.00K) | (3.83M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (75.56M) | (36.56M) | (74.40M) | 24.14M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (75.56M) | (36.56M) | (74.40M) | 24.14M | |
Net Income Growth
| -116.46% | +51.62% | -103.51% | +132.44% | |
Net Margin Growth
| -34.42% | -12.33% | -20.61% | +5.41% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (75.56M) | (36.56M) | (74.40M) | 24.14M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (75.56M) | (36.56M) | (74.40M) | 24.14M | |
EPS (Basic)
| -1.113 | -0.511 | -1.0242 | 0.3156 | |
EPS (Basic) Growth
| -69.74% | +54.09% | -100.43% | +130.81% | |
Basic Shares Outstanding
| 67.89M | 71.55M | 72.64M | 76.48M | |
EPS (Diluted)
| -1.113 | -0.511 | -1.0242 | 0.3088 | |
EPS (Diluted) Growth
| -69.74% | +54.09% | -100.43% | +130.15% | |
Diluted Shares Outstanding
| 67.89M | 71.55M | 72.64M | 78.16M | |
EBITDA
| (37.77M) | (8.36M) | 15.13M | 56.67M | |
EBITDA Growth
| -65.02% | +77.86% | +280.90% | +274.69% | |
EBITDA Margin
| -17.21% | -2.82% | +4.19% | +12.71% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 47.636 | |
| Number of Ratings | 13 | Current Quarters Estimate | 0.392 | |
| FY Report Date | 12 / 2025 | Current Year's Estimate | 1.647 | |
| Last Quarter’s Earnings | 0.51 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 0.31 | Next Fiscal Year Estimate | 1.615 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 12 | 12 | 12 | 12 |
| Mean Estimate | 0.39 | 0.35 | 1.65 | 1.62 |
| High Estimates | 0.41 | 0.44 | 1.67 | 2.08 |
| Low Estimate | 0.34 | 0.27 | 1.60 | 1.21 |
| Coefficient of Variance | 5.06 | 15.44 | 1.34 | 13.39 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 10 | 10 | 9 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 2 | 2 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 1 | 1 | 1 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Veracyte Inc - VCYT
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Veracyte Inc - VCYT
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jun 24, 2025 | Robert S. Epstein Director | 73,919 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 24, 2025 | Evan Jones Director | 43,664 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 24, 2025 | Karin Eastham Director | 23,228 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 24, 2025 | D. Brent Shafer Director | 25,828 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 24, 2025 | Jens Holstein Director | 37,199 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 24, 2025 | Tom Miller Director | 25,828 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 24, 2025 | Muna Bhanji Director | 39,310 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 24, 2025 | Eliav Barr Director | 51,189 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | John Leite Chief Commercial Officer-CLIA | 100,249 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $31.96 per share | 3,203,958.04 |
| Mar 11, 2025 | John Leite Chief Commercial Officer-CLIA | 105,260 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $31.04 per share | 3,267,270.40 |
| Mar 11, 2025 | John Leite Chief Commercial Officer-CLIA | 107,660 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | Annie McGuire SVP, General Counsel | 100,508 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | Phillip G. Febbo Chief Scientific & Med Officer | 106,700 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | Marc A. Stapley Chief Executive Officer; Director | 358,636 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | Rebecca Chambers Chief Financial Officer | 143,899 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2025 | Jonathan Wygant VP, Chief Accounting Officer | 49,763 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Phillip G. Febbo Chief Scientific & Med Officer | 82,540 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $33.95 per share | 2,802,233.00 |
| Mar 7, 2025 | Marc A. Stapley Chief Executive Officer; Director | 268,035 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $34.37 per share | 9,212,362.95 |
| Mar 7, 2025 | Marc A. Stapley Chief Executive Officer; Director | 269,129 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $33.91 per share | 9,126,164.39 |